AVN944 + gemcitabine

AVN944 + gemcitabine is a **combination therapy** investigated primarily for the treatment of pancreatic cancer. **AVN944** is an oral small molecule drug that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides and leading to cell cycle arrest and apoptosis in rapidly proliferating cells. **Gemcitabine** is a nucleoside analog used as a chemotherapeutic agent that inhibits DNA synthesis, leading to apoptosis in cancer cells. Together, this combination aims to exploit dual antitumor mechanisms, with AVN944 enhancing the cytotoxic effects of gemcitabine through metabolic deprivation and direct cytotoxicity, with evidence of activity in solid tumors such as pancreatic cancer[1][5][7]. Clinical studies have investigated safety, dosing, and efficacy of the combination in pancreatic cancer[1][5][7].

Brand names

AVN944 + gemcitabine

Other names

AVN944 in combination with gemcitabineAVN-944 in combination with gemcitabineAVN 944 in combination with gemcitabine